PRT-2527 is under clinical development by Prelude Therapeutics and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase I drugs for Diffuse Large B-Cell Lymphoma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PRT-2527’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PRT-2527 overview
PRT-2527 is under development for the treatment of relapsed/refractory hematologic malignancies including, diffuse large b-cell lymphoma, follicular lymphoma, primary mediastinal b-cell lymphoma, aggressive B-cell lymphoma subtypes, T-Cell lymphomas, mantle cell lymphoma (MCL), and chronic lymphocytic lymphoma (CLL)/small lymphocytic lymphoma (SLL), including Richter's syndrome, acute myelocytic leukemia, non-small cell lung cancer and solid tumors including sarcomas, human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer), hormone refractory (castration resistant, androgen-independent) prostate cancer, breast cancer and other cancers with genomic alterations that lead to MYC dependence. It is administered through intravenous route. The drug candidate acts by targeting cyclin dependent kinase 9 (CDK9).
It was also under development for the treatment of triple-negative breast cancer (TNBC), synovial sarcoma.
Prelude Therapeutics overview
Prelude Therapeutics (Prelude) is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The company product pipeline includes PRT1419, a potent, selective inhibitor of MCL1, PRT2527, a potent and highly selective CDK9 inhibitor and PRT3645, a next-generation CDK4/6 inhibitor. Prelude others pipeline includes PRT3789 a first-in-class SMARCA2/BRM protein degraded. It also carries out clinical trials. The company serves throughout the US . Prelude is headquartered in Wilmington, Delaware, the United States.
For a complete picture of PRT-2527’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.